These two samples belonged to patients with recurrent metastatic melanomas that have been previously treated with MAPK inhibitors, which is consistent with the notion that NRAS mutation can arise through a resistance mechanism following targeted therapy [24]. This evidence concerns the gene NRAS and melanoma.